PaulJSabbatiniMD

Gynecologic Cancer, Hematologic Oncology

Professor of Medicine, Cornell University-Weill Medical College, Deputy Physician-In-Chief for Clinical Research, Memorial Sloan Kettering Cancer Center

Request Appointment

Overview of Dr. Sabbatini

Dr. Paul Sabbatini is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, New York-Presbyterian Hospital, and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from University of Mississippi School of Medicine and has been in practice 28 years. Dr. Sabbatini accepts several types of health insurance, listed below. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 375 doctors at New York-Presbyterian Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(678) 792-0595

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
Vanderbilt University Medical CenterResidency, Internal Medicine, 1989 - 1993
University of Mississippi School of MedicineClass of 1989

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 1994 - 2026
NJ State Medical License 2020 - 2025
TN State Medical License 1990 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2011-2014
New York Magazine: Top Doctors Castle Connolly, 2012, 2014

Clinical Trials

Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 1998 Jan 01
Completed
Phase 1
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer Start of enrollment: 1998 Nov 01
Completed
Phase 2
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 1998 Dec 01
Completed
Phase 2
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer Start of enrollment: 2000 Feb 01
Completed
Phase 1
Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 2
Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum Start of enrollment: 2000 Sep 01
Completed
Phase 2
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer Start of enrollment: 2001 Feb 01
Completed
Phase 1, Phase 2
Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2001 Mar 01
Completed
Phase 1
CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer Start of enrollment: 2002 Sep 01
Completed
Phase 2
Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Start of enrollment: 2002 Dec 01
Completed
Phase 1
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients Start of enrollment: 2006 Dec 01
Terminated
Phase 2, Phase 3
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission Start of enrollment: 2007 Jul 01
Terminated
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2008 Mar 01
Completed
Phase 1
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
Withdrawn
Phase 3
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission Start of enrollment: 2010 Jul 01
Completed
Phase 2
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab Start of enrollment: 2010 Oct 01
Completed
Not Applicable
Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission Start of enrollment: 2010 Nov 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

36 citations
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.
Sarah P Suehnholz, Moriah H Nissan, Hongxin Zhang, Ritika Kundra, Subhiksha Nandakumar
Cancer Discovery. 2024-01-12
3 citations
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Ryan M Kahn, Pier Selenica, Thomas Boerner, Kara Long Roche, Yonghong Xiao
Gynecologic Oncology. 2024-01-01
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Aaron M Praiss, Austin Miller, Judith Smith, Stuart M Lichtman, Michael Bookman
Gynecologic Oncology. 2023-07-01

Journal Articles

A Phase 1 Dose-Escalation Study of Intraperitoneal Cisplatin, intravenous/intraperitoneal Paclitaxel, Bevacizumab, and Olaparib for Newly Diagnosed Ovarian Cancer
Karen A Cadoo, Roisin E O'Cearbhaill, Dmitriy Zamarin, Paul J Sabbatini, William P Tew, Carol Aghajanian, Jason A Konner, Gynecologic Oncology

Press Mentions

University of Mississippi Medical Center: People of the U: Paul SabbatiniSeptember 14th, 2021
How Cancer Clinical Trials Have Changed During the PandemicJune 16th, 2020
Miami Cancer Institute Has 55 Clinical Trials OngoingFebruary 27th, 2018
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment